Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer Avanir Pharmaceuticals (NASDAQ: AVNR) has received a distressing two-star ranking.
With that in mind, let's take a closer look at Avanir, and see what CAPS investors are saying about the stock right now.
Avanir facts
|
Headquarters (founded) |
Aliso Viejo, Calif. (1988) |
|
Market Cap |
$428.3 million |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$41.3 million |
|
Management |
CEO Keith Katkin (since 2007) CFO Christine Ocampo (since 2008) |
|
Return on Capital (average, past 3 years) |
(66.7%) |
|
Cash/Debt |
$69.8 million / $28.9 million |
|
Competitors |
Bristol-Myers Squibb (BMY +2.11%) Eli Lilly (LLY +1.93%) GlaxoSmithKline (GSK +1.83%) |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 26% of the 250 members who have rated Avanir believe the stock will underperform the S&P 500 going forward.
Just yesterday, one of those Fools, All-Star zzlangerhans, succinctly summed up the Avanir bear case for our community:
Nuedexta revenues have been increasing steadily, but not enough to justify a rebound from [$2.16 to $3.16] and a market cap of [$432M] despite an ongoing double digit quarterly burn and only [$70M] in the bank as of the end of Q3. I suspect traders are looking for positive news on Nuedexta from the [Committee for Medicinal Products for Human Use], but European approval is a notorious false start for companies with products that are already approved in the US. Other pipeline compounds remain in early clinical development.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
